TY  - CONF

T1  - SAFETY OF CYTOTOXIC CHEMOTHERAPY FOLLOWING RADIUM-223 CHLORIDE (RA-223) THERAPY IN THE PHASE 3 ALSYMPCA STUDY IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC) WITH BONE METASTASES

JO  - ANNALS OF ONCOLOGY

PY  - 2012/09/01

AU  - Sartor O

AU  - Coleman RE

AU  - Nilsson S

AU  - Vogelzang N

AU  - Cross A

AU  - O'Bryan-Tear G

AU  - Staudacher K

AU  - Garcia-Vargas JE

AU  - Zou J

AU  - Parker C

ED  - 

VL  - 23

SP  - 308

EP  - 309

Y2  - 2025/10/10

ER  -